Reviva Common Stock Total Equity from 2010 to 2024

RVPHW Stock  USD 0.22  0.01  4.35%   
Reviva Pharmaceuticals Common Stock Total Equity yearly trend continues to be fairly stable with very little volatility. Common Stock Total Equity will likely drop to 847.55 in 2024. Common Stock Total Equity is the total value of common stock equity held by shareholders, representing their ownership interest in the company. View All Fundamentals
 
Common Stock Total Equity  
First Reported
2010-12-31
Previous Quarter
1.1 K
Current Value
847.55
Quarterly Volatility
160.42351055
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Reviva Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Reviva Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 10 K, Net Interest Income of 523.9 K or Interest Income of 523.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 22.5. Reviva financial statements analysis is a perfect complement when working with Reviva Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Reviva Pharmaceuticals Correlation against competitors.

Latest Reviva Pharmaceuticals' Common Stock Total Equity Growth Pattern

Below is the plot of the Common Stock Total Equity of Reviva Pharmaceuticals Holdings over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Reviva Pharmaceuticals' Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Reviva Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Common Stock Total Equity10 Years Trend
Slightly volatile
   Common Stock Total Equity   
       Timeline  

Reviva Common Stock Total Equity Regression Statistics

Arithmetic Mean723.87
Geometric Mean708.98
Coefficient Of Variation22.16
Mean Deviation141.16
Median618.00
Standard Deviation160.42
Sample Variance25,736
Range443
R-Value0.79
Mean Square Error10,450
R-Squared0.62
Significance0.0005
Slope28.31
Total Sum of Squares360,300

Reviva Common Stock Total Equity History

2024 847.55
2023 1061.45
2020 923.0

About Reviva Pharmaceuticals Financial Statements

Reviva Pharmaceuticals investors use historical fundamental indicators, such as Reviva Pharmaceuticals' Common Stock Total Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Reviva Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Common Stock Total Equity1.1 K848

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Reviva Stock Analysis

When running Reviva Pharmaceuticals' price analysis, check to measure Reviva Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reviva Pharmaceuticals is operating at the current time. Most of Reviva Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reviva Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Reviva Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reviva Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.